Navigation Links
Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Date:12/9/2008

rombosis and pulmonary embolism. Anti-platelet therapy is used most often to treat and prevent thrombosis in arteries. The worldwide market for anti-platelet drugs in 2008 is estimated at over $8 billion driven by Plavix and is expected to grow to over $14 billion by 2020.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concepts that are engineered to provide significant advances over current treatments for cardiovascular disease, inflammatory disease and cancer.

Portola's two lead Phase II compounds, betrixaban, an oral Factor Xa inhibitor and PRT060128, an ADP receptor antagonist, target the global multi-billion dollar antithrombotic market. Both product candidates have best-in-class features versus current and novel agents in development and address the hospital, specialty, and chronic care markets. The Company's earlier-stage programs leverage Portola's chemistry capability to develop specific Syk and JAK inhibitors to treat cancer and inflammatory diseases. The company also has a novel FXa inhibitor antidote program with the potential to help manage the more than 20 million patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit http:/www.portola.com.


'/>"/>
SOURCE Portola Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
2. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
3. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
8. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
9. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
10. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
11. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Dec. 17 Transgenomic, Inc. (OTC Bulletin ... agreement with Gene Solutions for an exclusive licensing ... in Parkinson,s disease patients that can form the ... for Parkinson,s disease. Transgenomic,s platform mitochondrial mutation detection ... a diagnostic test that evaluates and quantitates the ...
(Date:12/17/2009)... Technologies, Inc. (formerly NTII) ("NTI") announced today ... the Secretary of State of the State of ... Dissolution generally become effective upon filing. The Certificate ... under the Delaware General Corporation Law. In ... Dissolution, NTI also closed its stock transfer books ...
(Date:12/17/2009)... 17 The Dr. Paul Janssen Award ... for nominations. The $100,000 Award recognizes individuals whose ... improvement of human health. Nomination forms are ... accepted until February 15, 2010. The Award winner ... the world,s top scientists, which features three new ...
Breaking Medicine Technology:Transgenomic, Inc. Executes License Option agreement for Parkinson's Disease Diagnostic Markers with Gene Solutions, LLC 2Transgenomic, Inc. Executes License Option agreement for Parkinson's Disease Diagnostic Markers with Gene Solutions, LLC 3Transgenomic, Inc. Executes License Option agreement for Parkinson's Disease Diagnostic Markers with Gene Solutions, LLC 4Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research 2Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research 3Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research 4AHA Board Elects John Bluford Chair Elect Designate 52607 1AHA Board Elects John Bluford Chair Elect Designate 52607 2AHA Board Elects John Bluford Chair Elect Designate 52607 3Anesiva Receives NASDAQ Delisting Staff Determination Letter 13175 1Anesiva Receives NASDAQ Delisting Staff Determination Letter 13175 2Anesiva Receives NASDAQ Delisting Staff Determination Letter 13175 3Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results 13174 1Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results 13174 2
(Date:12/17/2009)... A pregnant woman, who has carefully examined her options for birth ... – realizes that her healthcare provider is not accustomed to providing ... match her provider’s practice style. , ... Silver Spring, ... pregnant woman, who has carefully examined her options for birth – ...
(Date:12/17/2009)... -- Fred Hutchinson Cancer Research Center scientist M. ... awarded the distinction of AAAS Fellow. Election as ... of the American Association for the Advancement of ... is a researcher in the Hutchinson Center,s Vaccine ... biostatistics at the University of Washington. She is ...
(Date:12/17/2009)... of Justice announced today that the United States ... into settlement agreements with three home health agencies ... to the New York Medicaid and Medicare programs. ... coverage for home health aides only if those ... proper training. The United States contended that Nursing ...
(Date:12/17/2009)... ,Hopenhagen, the city is calling itself, ... international conference on climate change. Narconon has its ... of the worldwide Narconon drug education ... from climate change. But the streets thrum with ... by with flashing blue lights - a youth ...
(Date:12/17/2009)... down on prevention, experts say , , THURSDAY, Dec. ... are getting better at treating heart attacks and ... the basic rules for preventing them, according to ... Topping the list: too little exercise, too much ... surveyed last year reported no activity vigorous enough ...
Breaking Medicine News(10 mins):Health News:Who Should Deliver Your Baby? New Tool Helps Expectant Parents Choose Their Health Care Provider 2Health News:Who Should Deliver Your Baby? New Tool Helps Expectant Parents Choose Their Health Care Provider 3Health News:M. Elizabeth Halloran Named AAAS Fellow 2Health News:M. Elizabeth Halloran Named AAAS Fellow 3Health News:M. Elizabeth Halloran Named AAAS Fellow 4Health News:Three New York City Home Health Agencies Pay $9.7 Million to the United States to Settle False Claims Act Claims 2Health News:Save the Planet. Stop Smoking Dope, Says Narconon 2Health News:Obesity, Inactivity Keeping Heart Health Stats Down 2Health News:Obesity, Inactivity Keeping Heart Health Stats Down 3
... New research shows inhaled insulin is effective and well ... treatment also provides glycemic control comparable to a conventional ... received either inhaled insulin with bedtime Ultralente or two ... Hypoglycemia, or the abnormal decrease of sugar in the ...
... study , 70 percent of all cigarettes consumed are ... psychiatric patients living in and out of group homes ... their nicotine and drug use. ,Results showed 28 ... smoked cigarettes, and 12 percent were nicotine dependent. Nicotine ...
... drugs may slow mental decline and improve symptoms of ... pilot study was conducted to test the drug on ... patients were followed for one year, twenty-five of the ... patients received a placebo. All of the patients in ...
... the most frequent causes of indigestion. Typical symptoms include heartburn, ... a high salt intake significantly increase the risk of acid ... ,Results of the study showed that people who smoked every ... to have acid reflux than non-smokers. Those who routinely added ...
... women being treated for cervical cancer may protect fertility ... procedure, surgeons removed an ovary and transplanted it into ... undergoing treatment for cervical cancer. ,Researchers say ... site with an implant over several months Instead it ...
... New research shows combining the drugs memantine and donepezil ... ,Researchers studied more than 300 patients with moderate ... donepezil when the study began. Donepezil works by preventing ... brain that is important for memory and other thinking ...
Other Medicine News:
Platelet Aggregation Profiler...
... Eclipse,Plus or 850 ECG medical ... capability. Doctors,maintain all the benefits ... and gain the,ability to view ... personal computers., With diagnostic-quality viewing ...
... The Vision5L Digital ... 5- or 7-lead, ... a signal preview,screen. ... using a compact,flash ...
... three contrast levels (high, 9.5 % and 6%) ... test is designed to detect very subtle changes ... evaluation or due to refractive surgery. The upper ... contrast and acuity levels as the lower two ...
Medicine Products: